Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapies for cancer treatment. Its portfolio includes small molecules and antibodies targeting immune checkpoints and cancer cell pathways, such as TIGIT, PD-1, and adenosine receptors. Arcus focuses on combination therapies for lung, gastrointestinal, renal, and other cancers, collaborating with partners like Gilead for development and commercialization, while leveraging third-party manufacturing and strategic licensing.
This description was generated via AI from an annual report. Updated about 1 year ago.